Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.079 CHF
−80.44 M CHF
5.40 M CHF
924.88 M
About MESOBLAST LIMITED
Sector
Industry
CEO
Silviu Itescu
Website
Headquarters
Melbourne
Founded
2004
ISIN
AU000000MSB8
FIGI
BBG00LVDZ3K3
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Finer Market Points: ASX Top 10 Momentum Stocks: 4 Apr 2024ASX:MSB AMEX:GLV AMEX:MAG NYSE:MMC NYSE:MMI NYSE:FND NYSE:TPC NASDAQ:PAA NYSE:PNR AMEX:USL
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first a
MSB squeezes stubborn longs to their death.. Off topic but as an leading indicator for "market timing" is when defensive stocks return to their original strongest demand zones from their origins of a past move & are met again for another strong rally, this seems it could to be happening to MBS, time will tell!
With that said overall mark
MSB - Trade PlanMSB has been consolidating until recently when it spiked higher and pulling back currently. This could be a buying opportunity as long as its 50SMA support holds. I will be watching price action at the current levels and targeting the upper Resistance level of $2.95 with a tight stoploss below the s
Reduction in Heart Attacks, Strokes and Cardiac DeathSingle Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left v
MSB gets Fast Track from FDA Looks like price is respecting trendline / uptrend.
Price is within range. Needs to break above resistance and stay above for bullish confirmation.
Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stock
MSB - Bullish (A Medium to Long Term Buying Opportunity)1. Price has plummeted down and stopped at exact upward sloping 50 Months Moving Average
2. Price got support exactly on the 200 Weeks Moving Average
3. Price got support at a very strong Monthly Support Level
I believe this is a great medium to long term buying buying opportunity, as price got sup
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of LWB is 0.850 CHF — it has increased by 69.66% in the past 24 hours. Watch MESOBLAST LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange MESOBLAST LTD stocks are traded under the ticker LWB.
LWB stock hasn't changed in a week, the month change is a 69.66% rise, over the last year MESOBLAST LTD has showed a 69.66% increase.
We've gathered analysts' opinions on MESOBLAST LTD future price: according to them, LWB price has a max estimate of 2.48 CHF and a min estimate of 1.24 CHF. Watch LWB chart and read a more detailed MESOBLAST LTD stock forecast: see what analysts think of MESOBLAST LTD and suggest that you do with its stocks.
LWB stock is 41.06% volatile and has beta coefficient of 1.25. Track MESOBLAST LTD stock price on the chart and check out the list of the most volatile stocks — is MESOBLAST LTD there?
Today MESOBLAST LTD has the market capitalization of 1.25 B, it has increased by 6.72% over the last week.
Yes, you can track MESOBLAST LTD financials in yearly and quarterly reports right on TradingView.
MESOBLAST LTD is going to release the next earnings report on Aug 27, 2025. Keep track of upcoming events with our Earnings Calendar.
LWB earnings for the last half-year are −0.04 CHF per share, whereas the estimation was −0.04 CHF, resulting in a 14.29% surprise. The estimated earnings for the next half-year are −0.03 CHF per share. See more details about MESOBLAST LTD earnings.
MESOBLAST LTD revenue for the last half-year amounts to 2.91 M CHF, despite the estimated figure of 2.71 M CHF. In the next half-year revenue is expected to reach 11.20 M CHF.
LWB net income for the last half-year is −40.74 M CHF, while the previous report showed −50.46 M CHF of net income which accounts for 19.26% change. Track more MESOBLAST LTD financial stats to get the full picture.
No, LWB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 5, 2025, the company has 73 employees. See our rating of the largest employees — is MESOBLAST LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MESOBLAST LTD EBITDA is −40.45 M CHF, and current EBITDA margin is −917.74%. See more stats in MESOBLAST LTD financial statements.
Like other stocks, LWB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MESOBLAST LTD stock right from TradingView charts — choose your broker and connect to your account.